What is the revenue and EPS growth rate for Allurion year over year?

What does Allurion do and what are its main business segments?

What were the key takeaways from Allurion’s earnings call?

What factors drove the changes in Allurion's revenue and profit?

Did Allurion beat or miss consensus estimates last quarter?

What were the key takeaways from Allurion's earnings call?

What is Allurion's gross profit margin?

What guidance did Allurion's management provide for the next earnings period?

- **FDA Approval Near**: Final PMA review phase with no requested data; inspections passed without issues.
- **Restructured for Growth**: Q3 2025 revenue $2.7M (-50% YoY) reflects strategic pivot; operating expenses down 29%.
- **Debt-Free Positioning**: $5M private placement strengthens balance sheet ahead of U.S. launch.
- **Innovative Platform**: Drug-eluting balloon and 12-month capsule in development to address adherence in chronic diseases.

**【CEO Summary Section】**
- **FDA Milestones**: Submitted final PMA module in June 2025; passed pre-approval and BIMO inspections with no findings. Day-100 meeting confirmed no additional clinical data needed, signaling final review phase.
- **Q3 2025 Financials**: Revenue $2.7M (down 50% YoY) due to strategic restructuring. Operating expenses decreased 29% to $10.9M, with adjusted loss narrowing 39% to $6.9M. Restructured balance sheet to achieve debt-free status via debt-for-equity exchange and $5M private placement.
- **Strategic Shift**: Focused on accounts offering combination therapy (Smart Capsule + low-dose GLP-1s). 50%+ GLP-1 discontinuation rate in clinics creates patient pipeline. New distributors onboarded in Q4 for 2026 growth.
- **R&D Innovations**: Collaborating on drug-eluting balloon for controlled GLP-1 delivery, addressing adherence challenges. Exploring longer-lasting capsule platform for multi-therapeutic delivery.

**【CFO Financial Commentary】**
- **Revenue & Gross Profit**: $2.7M (49% gross margin) vs. $5.4M (58% margin) YoY. Lower production volumes reduced overhead absorption.
- **Expense Reductions**: 
  - Sales & Marketing: $3.1M (-40% YoY)
  - R&D: $2.0M (-38% YoY)
  - G&A: $5.8M (-14% YoY)
- **Liquidity**: $6.1M cash + $5M private placement as of Q3 end.

**【Q&A Highlights】**
- **U.S. Market Strategy**: Leverage international success in combination therapy to target U.S. clinics with high GLP-1 churn. Expected sequential Q4 growth and 2026 expansion.
- **Drug Delivery Platform**: Long-term vision for 12-month capsule delivering therapeutics/ microbiome enhancers. Potential to address adherence in chronic diseases beyond obesity.
- **Revenue Outlook**: Q4 2025 sequential growth; 2026 driven by GLP-1 price drops and new agent launches increasing discontinuation rates.

Allurion Technologies Inc. (ALUR) Q3 2025 Earnings Call Transcript

- **Strategic Shift**: Allurion pivots to combination therapy with low-dose GLP-1s, targeting 50%+ adherence improvement and metabolically healthy weight loss. 
- **Financial Impact**: Q2 revenue down 72% YoY ($3.4M) due to distributor transitions, but direct markets grow 20%. Operating expenses cut 48% YoY. 
- **FDA Milestone**: PMA submission complete; AUDACITY Study analyses exceed super-superiority margins (4.34% vs. 3.14% at 48 weeks). 
- **Cost Efficiency**: Combo therapy reduces GLP-1 costs abroad; U.S. pricing expected to decline, enabling similar strategy. 
- **Cash Position**: $12.7M cash; restructuring charges of $1.5M in Q3 for 2026 expense reduction.

**【CEO Summary Section】**
- **Strategic Pivot to Combination Therapy**: Shifted focus to metabolically healthy weight loss by combining the Allurion Balloon with low-dose GLP-1s, addressing adherence challenges (30% discontinuation within first month, 50%-75% by year). Key pillars include: 
  1. Commercial focus on accounts delivering comprehensive obesity care (20% QoQ growth in pilot markets). 
  2. R&D pipeline for drug-eluting balloons and next-gen balloon tech. 
  3. Clinical validation through multicenter European study (protocol submitted to IRBs, targeting 0.25mg semaglutide escalation). 
- **Q2 Financials**: Revenue $3.4M (vs. $11.8M YoY), down due to distributor transitions but +20% growth in direct markets. Operating expenses decreased 48% YoY, operating loss improved 26%. 
- **FDA Update**: Submitted final PMA module for Allurion Balloon, with AUDACITY Study analyses showing 4.34% weight loss superiority (p=0.0142) and 4.90% at 40 weeks (p=0.0006). 
- **Restructuring**: $1.5M Q3 charges for aligning expenses with new strategy. 

**【CFO Financial Commentary】**
- **Revenue**: $3.4M (74% gross margin) vs. $11.8M (76% margin) YoY, driven by distributor transitions and France suspension. 
- **Expenses**: 
  - Sales & Marketing: $2.4M (-64% YoY). 
  - R&D: $1.8M (-58% YoY). 
  - G&A: $5.2M (-29% YoY). 
- **Liquidity**: $12.7M cash as of June 30, 2025. 

**【Q&A Highlights】**
- **Cost Effectiveness**: Abroad, low-dose GLP-1s + Allurion reduce costs and side effects; U.S. pricing expected to decline. Combo therapy improves adherence and long-term health economics. 
- **Distributor Impact**: Transitioning Latin America/Middle East distributors, expecting disruption in 2025 but long-term growth. 
- **FDA Timeline**: 12-month review clock started; additional AUDACITY analyses may accelerate approval. 
- **Expense Outlook**: 50%+ operating expense reduction in 2026 post-restructuring. 
- **France Relaunch**: Expanded GLP-1 access in France driving interest in combo therapy. 
- **Coach Iris**: No Q2 updates, but ongoing development for proactive patient engagement.

Allurion Technologies Inc. (ALUR) Q2 2025 Earnings Call Transcript

- **Strategic pivot delivers results**: Q1 2025 operating loss narrows 48% YoY to $5.9M with 75% gross margin
- **FDA approval on track**: PMA submission by end-June, targeting 2025 approval
- **Clinical innovation**: Prospective trial of low-dose GLP-1 + balloon aims for 21% weight loss while preserving muscle
- **Ex-US growth engine**: 40% QoQ growth in B2B2C pilot clinics
- **Cash runway secure**: $20.4M cash as of Q1, sufficient for 2025 milestones

**【CEO Opening Remarks】**
- Q1 2025 revenue: $5.6M (down 40% YoY) with adjusted operating expenses of $10.1M (45% YoY decline). Adjusted net operating loss narrowed to $5.9M (48% YoY reduction). Gross margin expanded to 75% (vs. 73% prior year, 45% Q4 2024). 
- Five strategic pillars: 
  1. B2B2C sales model (40% QoQ growth in pilot clinics) 
  2. FDA approval for Allurion Balloon (PMA submission by end-June) 
  3. Ex-US profitability by end-2025 
  4. AI product platform expansion 
  5. France market reactivation
- Clinical trial update: Prospective study of 75+ patients combining Allurion Balloon with low-dose semaglutide to begin H2 2025, targeting 21%+ weight loss with muscle preservation.

**【CFO Financial Highlights】**
- Q1 2025 financials: 
  - Revenue: $5.6M (vs. $9.4M Q1 2024)
  - Gross profit: $4.2M (75% margin vs. 73% prior year)
  - Opex: 
    - Sales & marketing: $3.6M (34% YoY decline)
    - R&D: $2.6M (53% YoY decline)
    - G&A: $5.2M (16% YoY decline)
  - Cash balance: $20.4M as of March 31, 2025
- FY 2025 guidance: ~$3M revenue with 50% YoY expense reduction

**【Q&A Key Takeaways】**
- FDA approval timeline: PMA submission by end-June, target approval in 2025
- France market: Expected to contribute ~$1M in 2025, full recovery by 2026
- Software revenue: <10% of total in 2025, potential US launch with AllurionMeds
- Clinical trial costs: Minimal impact on 2025 budget, ~$1M total spend
- Tariff impact: Nil on gross margin (US-manufactured balloons)

Allurion Technologies Inc. (ALUR) Q1 2025 Earnings Call Transcript

- **Innovative Combination Therapy**: 20% weight loss with low-dose GLP-1s + balloon preserves muscle mass, outperforming standalone GLP-1s.
- **2025 Growth Catalysts**: B2B2C model pilots show 30% QoQ growth; FDA PMA submission Q2 2025; France resumption in Q1 2025.
- **Financial Restructuring Success**: OpEx down 39% YoY in Q4; 2025 OpEx targeted at -50% YoY with sales team expansion.
- **Path to Profitability**: Ex-U.S. EBITDA positive by 2026; gross margin expansion as France resumes and inventory normalizes.

**【CEO Vision and Strategic Update】**
- **Combination Therapy Innovation**: The Allurion Balloon paired with low-dose GLP-1s achieved 20% total body weight loss in 52 patients, preserving lean muscle mass and improving adherence. This approach mimics bariatric surgery without invasiveness.
- **2024 Financial Performance**: Q4 revenue $5.6M (FY24: $32.1M), down 32% YoY due to France suspension. Procedure volumes grew 4% YoY, driven by patients discontinuing GLP-1s.
- **2025 Strategic Pillars**: 
  1. **Commercial Restructuring**: Shift to B2B2C model, hiring 30%+ new reps, and pilot markets showing 30% QoQ procedure growth.
  2. **FDA Approval Pathway**: AUDACITY trial top-line success; PMA submission expected Q2 2025.
  3. **Ex-U.S. Profitability**: Target EBITDA positive by 2026; France resumption in Q1 2025 with full contribution in 2026.
  4. **AI Platform Scaling**: Launch next-gen balloon with smaller capsule and enhanced Virtual Care Suite features.
  5. **Capital Position**: $15.4M cash as of Q4, with runway into 2026.

**【CFO Financial Highlights】**
- **Q4 2024 Results**: 
  - Revenue: $5.6M (-32% YoY)
  - Gross Profit: $2.5M (45% margin vs. 78% FY23)
  - OpEx: $19.7M (-39% YoY)
  - Loss: $17.1M (-33% YoY)
- **FY24 Results**: 
  - Revenue: $32.1M
  - Gross Profit: $21.5M (67% margin)
  - OpEx: $61.9M
- **2025 Outlook**: 
  - Revenue: $30M (vs. $32.1M FY24)
  - OpEx: -50% YoY
  - Gross Margin: Expansion as France resumes and inventory normalizes.

**【Q&A Key Takeaways】**
- **Combination Therapy Validation**: Prospective trials planned to confirm 20% weight loss, muscle preservation, and adherence benefits.
- **2025 Revenue Cadence**: Steady QoQ growth driven by B2B2C pilots and new rep hiring; France contribution minimal in 2025.
- **FDA Timeline**: PMA submission Q2 2025; U.S. launch contingent on FDA feedback and capital efficiency.
- **Gross Margin Recovery**: Q1 2025 margin similar to H1 2024; France resumption to drive further expansion in 2026.

ALUR

ALUR fundamentals

Earnings Call

You can ask Aime